Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 125,606

Document Document Title
WO/2017/082396A1
The purpose of the present invention is to provide a method for the industrial production of lacosamide having high optical purity at a high yield, inexpensively, and safely. Provided is a method for the industrial production of lacosami...  
WO/2017/083700A1
Disclosed are conjugates and compositions comprising an amyloid beta binding protein conjugated to a MerTK ligand. Disclosed are methods of clearing amyloid beta aggregates from a subject comprising administering a therapeutically effect...  
WO/2017/079833A1
The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.  
WO/2017/080967A1
The present invention provides pharmaceutical compositions comprising a compound of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is conc...  
WO/2017/079834A1
The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.  
WO/2017/082121A1
This sustained-release topically administered agent includes: a compound having a pharmacological action; a crosslinkable polysaccharide derivative in which at least one active ester group capable of reacting with an active hydrogen-cont...  
WO/2017/078175A1
The present invention relates to an enhancer of the anti-dementia activity of royal jelly, which comprises limonene.  
WO/2017/077082A1
The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of su...  
WO/2017/076356A1
Disclosed are a novel crystal form of Flibaserin, and a preparation method therefor. The novel crystal form of Flibaserin of the present invention is named a crystal form I and a crystal form II. Compared with an existing crystal form, t...  
WO/2017/079455A1
Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of t...  
WO/2017/079734A1
Methods and pharmaceutical compositions are provided, which make use of compounds disclosed herein, including (I). The methods and compositions are useful for producing local or regional anesthesia or analgesia in nerve tissue of a subject.  
WO/2017/076900A1
The present invention relates to a novel [l,2,4]triazolo[l,5-a]pyrimidin-yl derivative of formula (1) as inhibitor of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compound, to p...  
WO/2017/076932A1
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from (II) R1 is S(0)2lower alkyl, S(0)2NR4R5, S(0)2c...  
WO/2017/077284A1
The invention relates to a silyl-containing polymer that is used, together with a tackifying resin to form an adhesive composition capable of storing and delivering drugs to the skin of a user. Typically the composition is formed into a ...  
WO/2017/075661A1
The present invention relates to methods and compositions for treating a condition associated with, or arising from, astrocyte dysfunction or glial scar formation or progression in an individual. The present invention is useful for, but ...  
WO/2017/079519A1
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, car...  
WO/2017/079391A1
The present invention provides compounds of Formula I and Formula II, and related compositions and methods.  
WO/2017/079161A3
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiat...  
WO/2017/076738A1
The present invention relates to a new process for preparing brivaracetam. (Ib)  
WO/2017/076825A1
The present invention provides (S)-N-(2-(4-chlorophenyl)-2-morpholinoethyl)-2- (pyrimidin-2-yl)-4-(trifluoromethyl)thiazole-5-carboxamide as P2X7 inhibitor, its use as a medicament, and a convenient enantiomeric synthesis protocol for th...  
WO/2017/077336A1
Polymeric nanoparticles comprising disulfiram or derivatives thereof, and their use in the treatment of cancer.  
WO/2017/075729A1
The present invention relates to an AAV/UPR-plus virus sequence, to a genetic treatment method, and to the use thereof in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, inter alia, as s...  
WO/2017/076737A1
The present invention relates to a continuous flow process for preparing brivaracetam.  
WO/2017/076169A1
The present invention provides a baicalein caffeine eutectic crystal, a preparation method therefor, a pharmaceutical composition, and application thereof. The baicalein caffeine eutectic crystal of the present invention has an excellent...  
WO/2017/076852A1
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein the substituents are defined in claim 1. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and nega...  
WO/2017/079467A1
Methods of the invention encompass delivery of nucleic acid sequences encoding ABCD1 for the treatment of X-linked Adrenoleukodystrophy (X-ALD), e.g., for Adrenomyeloneuropathy (AMN).  
WO/2017/077292A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic Μ1 and M4 receptors. Also provided are pharmaceutical composition...  
WO/2017/079641A1
Provided herein are small molecule compounds of the following formula (I): or a stereoisomer, tautomer, solvate, ester or pharmaceutically acceptable salt thereof, wherein A, B, C, Li, L 2, Ri, R 2, R 3, R 4, R 5, w, x, y and z are as de...  
WO/2017/076842A1
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein the substituents are defined in claim 1. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and nega...  
WO/2017/076931A1
The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from or the oxygen atom may form together with two n...  
WO/2017/075610A1
The present specification provides methods of treating nervous system disorders with a thyroid hormone neutral dose of a RXR agonist to promote remyelination or neuroprotection or both and thereby maintain or regenerate healthy axons and...  
WO/2017/073232A1
The present invention addresses the problem of providing a neural vascular barrier failure inhibitor, said inhibitor acting on vascular barrier failures caused not only by a hypoxic state but also by various other factors, and a therapeu...  
WO/2017/071536A1
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2017/073709A1
A compound represented by formula (1) or salt thereof which has an inhibitory effect on mPGES-1, and is useful as an active ingredient for a medicinal drug for preventing and/or treating a disease such as inflammation, pain, rheumatism, ...  
WO/2017/075013A1
The present invention provides methods and compositions for promoting recovery of function from neurologic injury, such as ischemic injury caused by acute stroke.  
WO/2017/072584A1
The present application relates to a method of treating a migraine headache in a patient by administering a pharmaceutical composition including rizatriptan or pharmaceutically acceptable salts thereof contained in a unit dose.  
WO/2017/073485A1
The present invention provides a novel peptide having the property of specifically accumulating in and directly acting on a glioma. The present invention is a peptide represented by any one of the following (a) to (c): (a) a peptide form...  
WO/2017/072721A1
The disclosures herein relate to novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associate...  
WO/2017/075119A1
A composition comprising at least one AAV vector formulated for intrathecal delivery to the central nervous system is described. The composition comprises at least one expression cassette which contains sequences encoding an immunoglobul...  
WO/2017/072099A1
The present invention relates to the compound ((2R,2'R)-bis(((tetrahydro-2H-pyran-4- carbonyl)oxy)methyl) 1,1'-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment o...  
WO/2017/072225A1
The invention concerns a pet food or a pet supplement comprising a synergistically-effective antioxidant composition comprising an extract of Vitis vinifera and an extract of Vaccinium angustifolium, wherein said composition comprises at...  
WO/2017/073710A1
The purpose of the present invention is to provide a compound that is effective as a prophylactic agent or a therapeutic agent for various diseases and symptoms associated with the orexin receptor, as well as to provide a medical usage t...  
WO/2017/071576A1
The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of gene...  
WO/2017/072083A1
The present invention relates to compounds of formula (I), wherein R1' is methyl; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, e...  
WO/2017/071716A1
A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is di...  
WO/2017/075192A1
The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof c...  
WO/2017/075580A1
Compositions and methods for treating, alleviating, and/or preventing one or more symptoms associated with axonal degeneration in individuals in need thereof, such as individuals with peroxisomal disorders and leukodystrophies include on...  
WO/2017/075540A9
Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologi...  
WO/2017/071799A1
The invention relates to methods of treating a central nervous system disorder in a subject, comprising reducing the level of LPA in the brain of said subject.  
WO/2017/072816A1
The present invention addresses the problem of providing a therapeutic agent for fibrotic diseases of the organs that can effectively suppress (or prevent) organ fibrosis such as renal fibrosis. The present invention solves this problem ...  

Matches 351 - 400 out of 125,606